# About Dr CJC-1295: An Independent Research Digest > Dr CJC-1295 is an independent editorial project that summarizes the peer-reviewed CJC-1295 research literature. Not a clinic, not a vendor — editorial commentary on published science. An independent editorial reading of the published literature — what the studies measured, what they did not, and why the distinction is the whole point. ## What Dr CJC-1295 is Dr CJC-1295 is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The site exists because the public conversation about this compound is unusually muddled. The two forms — DAC and no-DAC — get conflated constantly, community 'protocols' are presented as if they were trial data, and the gap between a measured pharmacokinetic finding and a real-world claim is rarely drawn clearly. The digest's job is to draw that line: to report the 5.8-to-8.1-day half-life and the days-long GH/IGF-1 elevation as the genuine findings they are [1], and to mark the absent longevity trial and the unsettled safety questions just as plainly. ## What the 'Dr' in the name means The 'Dr' in Dr CJC-1295 is editorial framing, not a claim about services. It signals the posture this publisher takes toward the literature — careful, measured, willing to read a study closely — not the presence of a physician, a clinic, or a prescription service. There are no doctors here to consult, no treatment offered, and nothing dispensed. If you want medical guidance about anything in your own life, that belongs with a licensed clinician who can see your full picture. What you will find here instead is a consistent method. Every quantitative claim is tied to a numbered citation. Findings from animals and cells are labeled as preclinical; findings from people are labeled as human. Where the evidence is strong, the digest says so without hedging. Where it is thin — and on long-term human safety for CJC-1295, it is thin — the digest says that too, because an honest gap is more useful than a confident guess. ## How the digest is built Each page is assembled from the published record: peer-reviewed journals, the foundational pharmacology, and recent reviews of the GHRH-analog class [13][14]. We avoid brand names and product framing entirely. We do not recommend doses, we report what studies administered. And we keep the regulatory facts visible rather than buried — CJC-1295 is unapproved, was not recommended for the 503A compounding bulks list at the 2024 FDA advisory committee, and is prohibited in sport. The aim is a calm, trustworthy reading you can check against the sources yourself. ## What we are not It is worth stating the negatives plainly, because the domain name could be misread. Dr CJC-1295 is not a pharmacy, not a clinic, and not a supplier. We do not fill prescriptions, hold inventory, or connect readers to sources, and nothing on this site should be read as an offer to sell. The compound discussed here is an unapproved research chemical, and the digest treats it as a subject of study, not a product. We also do not speak for any manufacturer, vendor, or sport organization. The regulatory and anti-doping facts we cite — the FDA advisory-committee outcome, the WADA prohibition — are reported because they are part of the public record a reader deserves to see, not because we represent any of those bodies. The single thing we do is read the literature carefully and show our work. Everything else, including any decision about your own health, belongs elsewhere. --- A calm, tactile reading of the CJC-1295 research record — the pharmacokinetic studies pressed up plainly and the human gaps marked just as clearly, with no clinic behind the name and nothing here dispensed.